Atorvastatin effectiveness and safety in patients with high cardiovascular risk. Revising the results of the OSCAR Study (2006)

• Main Authors: S. A. Shalnova, A. D. Deev, N. V. Kiseleva
• Format: Article
• Language: Russian
• Published: «SILICEA-POLIGRAF» LLC 2010-12-01
• Series: Кардиоваскулярная терапия и профилактика
• Subjects: high-risk patients; lipid metabolism; statins; oscar study
• Online Access: https://cardiovascular.elpub.ru/jour/article/view/2145

Aim. To investigate the effects of a atorvastatin (Atoris, KRKA) on major clinical parameters in patients with high cardiovascular risk – the participants of the OSCAR Study (2006). Material and methods. The total number of high-risk patients was 930 (472 men). The mean age was 57,8 years. Coronary heart disease (CHD) was diagnosed in 80,1% of men and 70,0% of women. All participants were divided into three groups by their CHD status: no CHD; with uncomplicated CHD; with CHD complications (myocardial infarction, stroke, and revascularisation in anamnesis). In all patients, the levels of risk factors, lipid profile, anthropometric and hemodynamic parameters were assessed. A generic atorvastatin was administered in a fixed start dose of 10-20 mg/d. The duration of the study was approximately 1,5 months. Results. After 8 weeks of Atoris treatment, a significant improvement in hemodynamic and lipid parameters was observed. In patients with CHD complications, lipid profile dynamics was less manifested, but the prevalence of target lipid level achievement was higher, since these individuals started with higher doses of atorvastatin. The total risk of fatal cardiovascular events reduced significantly. Atorvastatin was well-tolerated. Conclusion. Atorvastatin (Atoris, KRKA) is effective and safe in real-world clinical practice. It reduces the risk of cardiovascular events and mortality, also improving quality of life in high-risk patients.